Stereotaxis Corp (STXS): Debts to Book Capitalization

Brandmark of Stereotaxis Inc (STXS)

A stable engineering staff and the recruitment of programmers ensure the technological sovereignty of Stereotaxis, Inc. (STXS). The company's environmental development vector is evident in its energy-saving solutions and the reduction of plastics used in system assembly. The price trend reflected below, recorded at 0.31, complements the business outlook for the arrhythmia-fighting robotics venture, which relies on the expansion of the Genesis platform and new licenses.

STXS - Stereotaxis Corporation Debts to Net Assets over the range 07/04/2022 - 10/27/2026
Original product of Stereotaxis Inc

This indicator determines the proportion of borrowed funds within the equity structure, allowing investors to assess the degree of financial leverage and the risk of insolvency. By analyzing the total debt-to-book equity ratio, one can evaluate whether Stereotaxis, Inc. (STXS) possesses sufficient resources to scale the Genesis system and implement telemedicine solutions without imposing a critical debt burden on the business.

Competitors of Stereotaxis, Inc.

BSX: Debts to Book Capitalization|Debts to Book Value edwards.com EW|RMD: Debts to Book Capitalization|PODD - Debt to Book Value|Zimmer Biomet - Debts to Book Capitalization|CooperSurgical (COO) - Debts to Net Assets|ALGN (Align Technology, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization GMED|Debt to Book Capitalization Ratio TransMedics Organ Care System (TMDX)|Debt to Book Capitalization Ratio Alphatec Holdings (ATEC)|Debts to Book Capitalization AORT|ENOV - Debts to Net Assets|Debt to Book Value Integra LifeSciences|ESTA - Debts to Book Capitalization Ratio|Debts to Book Capitalization BBNX|IRADIMED Corp (IRMD) - Debts to Book Value|Debts to Book Capitalization Embecta Inc. (EMBC)|Debt to Book Value Ratio Tandem Corp (TNDM)|AxoGen, Inc. (AXGN) - Debt to Book Value|Debt to Net Assets Ratio SIBN (si-bone.com)|Orthofix - Debt to Book Capitalization Ratio|Debt to Book Value Bioventus Inc BVS|KIDS (OrthoPediatrics Inc.) - Debts to Book Capitalization|TMCI - Debts to Book Value|Debts to Book Capitalization Strata Critical Medical Inc|carlsmed.com (CARL) - Debt to Book Value Ratio|RXST: Debts to Book Capitalization|Debts to Net Assets ClearPoint|Debts to Book Capitalization STIM (NeuroStar)|Debt to Book Value Sight Sciences Inc (SGHT)|Debts to Book Capitalization OBIO (Orchestra BioMed, Inc.)|Anika Therapeutics Inc. - Debts to Book Capitalization|NSPR - Debt to Book Capitalization Ratio|Jin Medical International (ZJYL) - Debt to Book Capitalization Ratio|Debt to Book Value vivani.com VANI|Xtant Medical (XTNT) - Debt to Net Assets Ratio|Debts to Book Capitalization NMTC (NeuroOne Medical Technologies)|Debts to Book Value MODD|MYO: Debt to Book Capitalization Ratio|Debt to Net Assets Envoy Medical Inc. COCH|Debt to Book Value VVOS (Vivos Therapeutics, Inc)|Debts to Book Capitalization enVVeno Corp NVNO|Debts to Book Capitalization SINT (SINTX Technologies)|TNON: Debts to Net Assets|Debt to Book Capitalization Ratio Lifeward (LFWD)|AMIX (Autonomix Medical) - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio IVF|Debt to Book Value Bone Biologics Inc|Axonics, Inc. - Debts to Book Capitalization|Debts to Book Value BIOL (biolase.com)|DYNT - Debt to Book Capitalization Ratio|FNA - Debt to Book Value Ratio|Debt to Book Value INVO Bio INVO